Ad Scientiam allows research and clinical studies to leverage new possibilities offered by the usage of smartphones. The Company's mobile applications integrate proprietary algorithms capable of steering patients more rapidly to a consultation, adapting its data to the patient state and reducing loss of chance for patients. Ad Scientiam has developed DAMS, which innovates in MS self-assessment and is used for the monitoring of multiple sclerosis and many other chronic diseases such as depression, rheumatoid arthritis, Parkinson's, etc.